Twitter LinkedIn
    Tuesday, May 24
    Login
    0 Shopping Cart
    Twitter LinkedIn
    Private Equity InsiderPrivate Equity Insider
    • About Us
    • Digital Events
    • Our Network
      • Reach
      • Sponsors
      • Members
    Private Equity InsiderPrivate Equity Insider
    Home»Investments»TPG Sells More Than 10% of Novotech to Investors Ahead of IPO
    Investments

    TPG Sells More Than 10% of Novotech to Investors Ahead of IPO

    January 31, 2021Updated:January 31, 20212 Mins Read
    LinkedIn Facebook Twitter Email WhatsApp
    Share
    LinkedIn Facebook Twitter Email WhatsApp

    Private equity firm TPG is selling more than 10% of its clinical research and testing provider Novotech Pty Ltd to a group of investors.

    The transaction will value Novotech at more than $2.3 billion as the company prepares for an initial public offering in Hong Kong later this year, said Joel Thickins, head of Australia and New Zealand for TPG Capital Asia. He is also chairman of Novotech.

    The valuation makes the company one of the most successful investments for the private equity group in Asia, he said. The Sydney-based firm has increased revenues by more than 30% a year under TPG’s ownership since 2017, most recently helping with clinical trials for Covid-19 vaccines, as well as cancer and hepatitis drugs.

    “Novotech is a platform asset for us in Asia and a testament to the sector-led strategy we have pursued in differentiating ourselves from other sponsors,” Thickins said in an interview.

    He said TPG decided to invest in the clinical research industry in Asia in 2015 on intensifying investor demand for biotech companies and because the region’s populations were relatively untested in clinical trials compared with the U.S. and Europe. To be able to offer clinical testing services to health-care companies in the U.S. and Europe was a big opportunity for the firm.

    TPG also helped Novotech expand overseas. The company operates in 12 countries, with 70% of its revenue generated outside of Australia, compared with just 30% three years ago. It’s among the largest biotechnology contract research businesses across China, Southeast Asia, Taiwan and South Korea, which together make up a number of the fastest-growing markets for clinical trials.

    Anand Tharmaratnam will take over from Thickins as chairman of the company in April, the company said last month.

    Source: Bloomberg

     

    Image Source

    Related

    Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.

    Investments investors IPO
    Share. LinkedIn Facebook Twitter Email WhatsApp

    Related Posts

    Vista Equity Partners Among the First Major U.S. Private Equity Firms to Advance Global ESG Strategy with Portfolio-Wide Participation in Climate Program

    May 23, 2022

    General Atlantic eyeing $2 bn investment in India, SE Asia

    May 23, 2022

    Air France-KLM Talking With Apollo on $528 Million Injection

    May 23, 2022

    Morgan Stanley Capital Partners Completes Investment in Fairway Lawns

    May 19, 2022

    Comments are closed.

    Other Articles

    Liverpool FC owner FSG seeks new teams and possible listing

    April 5, 2021

    KKR to Acquire Leading Japanese Real Estate Asset Manager from Mitsubishi Corporation and UBS Asset Management in a Strategic Transaction

    March 17, 2022

    Apollo Mulls Merging Yahoo Sports With Betting Firms, Including PointsBet, to create +$1bn gambling giant

    March 4, 2022

    Inflexion to buy into e-bike component maker enviolo for $245m, eyeing sustainable mobility transition

    February 10, 2022

    Private Equity Insider LLC
    1212 Avenue of the Americas
    New York City 10036
    USA

    [email protected]

    Twitter LinkedIn
    © 2022 Private Equity Insider LLC. All rights reserved.
    • About
    • Terms of Use
    • Cookie Policy
    • Privacy Policy
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.

    View Cart Checkout Continue Shopping

    Sign In or Register

    Welcome Back!

    Login to your account below.

    Lost password?